Bacterial Pneumonia

11/01/2015 - "We first treated him with antibiotics(PIPC/TAZ plus GRNX), suspecting bacterial pneumonia. "
01/01/2014 - "As WHO guidelines do not make a distinction between viral and bacterial pneumonia, these children continue to receive antibiotics because of the concern that it may not be safe to do otherwise. "
01/01/2013 - "Thus, inhibiting STAT1 in combination with antibiotics may be a novel therapeutic strategy to address inefficient resolution of bacterial pneumonia."
09/14/2011 - "Such markers would minimize inappropriate diagnosis of false positive cases and treatment with antibacterial agents, while increasing positive predictive values for diagnosis of bacterial pneumonia. "
05/01/2011 - "Children aged 2 months to 18 yrs who were mechanically ventilated, had an abnormal chest radiograph, and for whom the attending physicians had initiated antibiotics for presumed bacterial pneumonia. "

10/01/2012 - "Preschool-aged children with uncomplicated bacterial pneumonia should be treated with amoxicillin. "
10/01/1998 - "To determine if intramuscular (IM) penicillin is more effective than oral (PO) amoxicillin in the early outpatient treatment of pediatric patients with presumed bacterial pneumonia. "
03/01/1986 - "[A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia]."
10/01/1998 - "There does not appear to be a significant difference between PO amoxicillin and IM penicillin in the early outpatient treatment of pediatric patients with presumed bacterial pneumonia."
06/01/1998 - "Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia."

12/01/2013 - "Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia."
09/01/2014 - "The Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE) is a multicenter registry study of patients treated with ceftaroline fosamil in the United States for ABSSSI or community-acquired bacterial pneumonia. "
08/01/2014 - "Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience."
12/01/2013 - "Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i.v.) every 12 h (q12h) for 5 to 7 days for community-acquired bacterial pneumonia (CABP) were conducted. "
03/01/2013 - "Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials."

03/01/1986 - "From these results of this trial, it is concluded that oral administration of 750 mg of S6472 twice a day (1,500 mg per day) is as effective and useful as that of 500 mg of ordinary CCL 3 times a day (1,500 mg per day) or 500 mg of AMPC 4 times a day (2,000 mg per day) in the treatment of bacterial pneumonia or lung abscess."
03/01/1986 - "[A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia]."
11/01/1988 - "[Comparative clinical study of CS-807 and cefaclor for bacterial pneumonia by a double-blind method]."
10/01/1991 - "Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia."
11/01/1990 - "The efficacy, safety and usefulness of BMY-28100 for the treatment of bacterial pneumonia were compared with those of cefaclor (hereinafter referred to as CCL) in a double-blind study. "

01/01/2009 - "He was initially diagnosed with bacterial pneumonia and treated with ceftriaxone without significant improvement. "
11/01/1990 - "The use of ceftriaxone for bacterial pneumonia in pediatric patients."
11/01/1990 - "Our data suggest that once daily intramuscular ceftriaxone can be successfully used for the outpatient treatment of most community-acquired severe bacterial pneumonias in children. "
11/01/1990 - "Ceftriaxone, a broad spectrum third-generation cephalosporin with a half-life of six to eight hours, was evaluated prospectively in 147 children with severe community-acquired bacterial pneumonia during the period 11/15/88-5/15/89. "
01/01/2015 - "A 14-year-old boy suffering from Crohn disease developed bacterial pneumonia that was treated with ceftriaxone. "

09/01/2012 - "In summary, ceftaroline resistance surveillance (Assessing Worldwide Antimicrobial Resistance Evaluation [AWARE] Program) in the United States (2008-2010) documented in vitro sustained potency and spectrum against Gram-positive and Gram-negative pathogens known to cause community-acquired bacterial pneumonia."
06/01/2012 - "Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08)."
01/01/2012 - "Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia."
04/01/2010 - "Ceftaroline is a renally excreted broad-spectrum cephalosporin that is clinically effective for the treatment of complicated skin and skin structure infections and community-acquired bacterial pneumonia, and it has distinctive activity against some difficult-to-treat multidrug-resistant gram-positive organisms."
04/01/2015 - "In this study, the probability of pharmacokinetic/pharmacodynamic target attainment (PTA) of ceftaroline against clinical isolates causing community-acquired bacterial pneumonia (CABP) and complicated skin and skin-structure infection (cSSSI) in Europe was evaluated. "

06/22/1992 - "Thus, these clinical trials support the conclusion that loracarbef is a safe and effective treatment for bacterial pneumonia."
06/22/1992 - "Loracarbef, a member of the carbacephem class of antibiotics, was tested in a series of clinical trials for its efficacy and safety in the treatment of lobar and bronchial bacterial pneumonia. "
03/01/1992 - "It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia."

01/01/2011 - "It demonstrates potent in vitro activity against causative pathogens that are most frequently isolated in patients with community-acquired bacterial pneumonia (CABP), including (but not limited to) Streptococcus pneumoniae (both penicillin-sensitive and -resistant strains), Haemophilus influenzae and Moraxella catarrhalis (including β-lactamase-producing strains), Klebsiella pneumoniae, and 'atypical organisms' (namely Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). "
09/01/2001 - "pneumoniae are often lethal and justify the penicillin prophylaxis, which has provided a dramatic decrease in early mortality bacterial pneumonia is common in patients younger than four years, with most cases being due to S. "
10/01/1996 - "The continuing emergence of antibiotic-resistant bacteria (e.g., penicillin-resistant pneumococci) suggests that bacterial pneumonia will assume increasing importance in the coming years. "
03/01/1995 - "This evaluation was based on a consecutive sample of 1822 adult patients (> 18 years of age) with documented or suspected bacterial pneumonia who were being treated with a cephalosporin, a penicillin, or an aminoglycoside over a 3-month period. "
04/01/1994 - "A total of 1822 adult patients with documented or suspected bacterial pneumonia who were receiving a cephalosporin, penicillin, or an aminoglycoside were enrolled. "

01/01/2011 - "Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia."
04/01/2013 - "Tigecycline has been shown to be as effective and safe as standard antimicrobial therapy for treatment of adults with complicated intra-abdominal infections, complicated skin and skin structure infections, and community-acquired bacterial pneumonia. "
01/15/2010 - "Tigecycline is effective in the treatment of complicated skin/skin-structure infection (cSSSI), complicated intraabdominal infection (cIAI), and community-acquired bacterial pneumonia (CAP), but its efficacy in subjects with secondary bacteremia is unknown. "
12/01/2011 - "Although it is approved by the Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia, emerged resistance of Acinetobacter spp. and limited therapeutic options left physicians no choice but to use tigecycline for off-label indications."
02/01/2011 - "Tigecycline is the first of a new class of antibiotics named glycylcyclines and it was approved for the treatment of complicated intra-abdominal infections and skin and skin structure infections and community-acquired bacterial pneumonia. "

01/01/1989 - "One hundred children with clinically diagnosed bacterial pneumonia were assigned at random to receive treatment with either amoxycillin (250 or 500 mg) or amoxycillin (250 or 500 mg) plus clavulanic acid (62.5 or 125 mg) 3-times daily, dosage and duration of treatment being determined by the severity of the condition. "
03/01/1992 - "It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia."
01/01/1989 - "An open, comparative evaluation of amoxycillin and amoxycillin plus clavulanic acid ('Augmentin') in the treatment of bacterial pneumonia in children."
01/01/2001 - "Sequential i.v./oral amoxicillin-clavulanate and parenteral ceftriaxone were equally safe and effective for the empirical treatment of acute bacterial pneumonia, including penicillin and cephalosporin-resistant pneumococcal pneumonia. "

12/01/2012 - "An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?"
07/01/2009 - "DLTs included febrile neutropaenia, thrombocytopaenia, bacterial pneumonia and delayed second cycle of chemotherapy. "
08/01/1993 - "We measured neutrophil's CL (CL-index) in 12 patients of the bacterial pneumonia three times per each case: before, during and after chemotherapy. "
08/01/1993 - "I: Change in neutrophil's CL by chemotherapy against the bacterial pneumonia]."
01/01/1982 - "[Chemotherapy of acute bacterial pneumonia]."

08/01/2010 - "Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!"
08/01/2010 - "A prototypical patient is presented to introduce important design issues for clinical trials of antibacterials in the treatment of ventilator-associated bacterial pneumonia."
12/01/2015 - "for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. "
01/01/2014 - "Now approved in the USA for the treatment of HABP, including ventilator-associated bacterial pneumonia, caused by susceptible isolates of S. "
09/01/2011 - "Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia."

05/01/2013 - "Impact of the prone position in an animal model of unilateral bacterial pneumonia undergoing mechanical ventilation."
05/01/2006 - "Thirteen adult patients with nosocomial bacterial pneumonia on mechanical ventilation were enrolled. "
04/01/2005 - "The aim of our review was to evaluate up to date facts regarding control of bacterial pneumonias during mechanical ventilation in intensive care unit settings."
04/01/2005 - "Control of bacterial pneumonia during mechanical ventilation."
05/01/2004 - "Ten adult patients with severe nosocomial bacterial pneumonia on mechanical ventilation. "

07/01/1991 - "The consequences of hospital-acquired bacterial pneumonia are a significant seven-, five-, and two-fold increase in mechanically ventilated days, intensive care, and hospital stay, respectively. "
09/01/1990 - "This article reviews the currently available invasive techniques for the diagnosis of bacterial pneumonia in the intensive care patient, with particular emphasis on the bronchoscopic methods using protected specimen brushes and bronchoalveolar lavage. "
03/01/1989 - "Colonization of the oropharynx with potentially pathogenic microorganisms (PPM) is a highly significant factor in the pathogenesis of bacterial pneumonia in intensive care patients. "
01/01/2014 - "Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit."
05/09/1987 - "Bacterial pneumonia is responsible for high mortality in surgical intensive care patients which is partly attributable to a high incidence of gram-negative bacillary pneumonia. "

01/01/1999 - "We present the case of a 12-year-old female with severe postoperative bacterial pneumonia unresponsive to conventional treatment following a failed renal transplant. "
05/01/1998 - "On day +6 after peripheral blood stem cell transplant (PBSCT) bacterial pneumonia developed. "
06/01/1992 - "Late bacterial pneumonia may occur more than 6 months after transplant because of prolonged immunedeficiency and functional asplenia. "
03/01/1990 - "The incidence of bacterial pneumonia is highest in recipients of heartlung (22%) and liver transplants (17%), intermediate in recipients of heart transplants (5%), and lowest in renal transplant patients (1 to 2%). "
05/01/2002 - "Bacterial pneumonia has been cited as the leading cause of infectious death in renal transplant recipients but has not been studied in a national transplant population. "